Vaccine policy drew competing evidence efforts today: HHS announced new vaccine-injury initiatives while the AMA and the University of Minnesota's Vaccine Integrity Project launched their own structured evidence review. Health care was also the only one of five sectors to cut spending commitments this spring, and remibrutinib picked up a new FDA label.
New to the briefing · Needs confirmation
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
HHS announces new vaccine-injury studies that advocates say will deepen mistrust
HHS touted new vaccine-injury initiatives that advocates say will further erode public trust.
Why it matters: If advocates are right that the initiatives deepen mistrust, physicians should expect more patient questions and hesitancy about vaccines in clinic.
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
AMA and Vaccine Integrity Project launch independent vaccine evidence review
The AMA and Vaccine Integrity Project launched a separate independent review of vaccine evidence.
Why it matters: A physician-led evidence review gives clinicians a separate reference point for counseling patients if federal messaging on vaccines gets contested.
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
Teladoc launches new AI features
Teladoc rolled out new AI features in its platform.
Why it matters: Hospital-facing AI tools are arriving inside enterprise platforms, so physicians may meet them in their workflow before anyone asks their opinion.
Physician forum debates whether AI will replace radiologists
Physicians in an online forum debated whether AI will replace radiologists.
Why it matters: The forum worry is less about replacement than about supervision burden and clinicians deferring to AI at the cost of their own skills.
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
WellSpan and Beth Israel Lahey unveil next CEOs
WellSpan and Beth Israel Lahey each announced their next chief executive officers.
Why it matters: New chief executives at WellSpan and Beth Israel Lahey can shift priorities on employment, staffing and contracting for physicians at those systems.
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
Health care is the only sector cutting spending commitments this spring
Health care was the only sector to cut spending commitments this spring, citing supply costs and physician pressures.
Why it matters: Reduced spending commitments tied to supply costs and physician pressures point to tighter budgets that can affect hiring and resources.
One independent source stands behind this story, or only discussion threads do. It is shown so you are not behind on it, and it keeps this label until a second independent outlet reports it. Reddit, Hacker News and X are shown as discussion and never count as confirmation. How every briefing is checked →
FDA expands remibrutinib label to symptomatic dermographism
Remibrutinib's FDA label was expanded to cover symptomatic dermographism, with a 29% response rate.
Why it matters: Dermatologists and allergists now have an oral BTK inhibitor option with a labeled indication for symptomatic dermographism, though the response rate was modest.
Initial safety and tolerability data from the gene-editing cholesterol drug, expected in Q1 2027
Whether the AMA and Vaccine Integrity Project review publishes findings that address the HHS vaccine-injury initiatives
Which clinics change hands and how staff are affected as Harbor Health takes over 27 VillageMD primary clinics
How this briefing was researched
53 sources read for this niche today. 3 couldn't stand as a citation and were set aside. 9 stories cleared the bar. Reddit, Hacker News and X are shown as discussion and never counted as corroboration. Built 01:24 UTC. How every briefing is checked →
Follow Physicians
This briefing in your inbox every Monday. We skip emails when there are no new stories to report.
Free · weekly · unsubscribe in one click · no account needed. Pro: daily, or the weekdays you pick.